| P/E (FY) | — | Sales (TTM) | €712,173 |
| Earnings (TTM) | -€32.6M | ROE | — |
| Net Margin | −4572.42% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −9.58% |
Sequana Medical NV develops and commercializes treatments for diuretic-resistant fluid overload associated with liver disease, cancer, and heart failure. Its products include the alfapump, an implantable system for refractory liver and malignant ascites, and Direct Sodium Removal (DSR) for fluid overload throughout the body. Founded in 2006 and headquartered in Gent, Belgium, the company operates in Belgium, Germany, France, and internationally.
| Market Cap | $18.5M | Trading Days | 1862 |
| 52W High | 1.62 |
| 52W Low | 0.46 |
| % Off High | −62.24% |
| YTD | −3.63% | 1Y | −56.73% |
| 3Y | −80.79% | 5Y | −91.49% |
| Since incept. (ann.) | −29.69% |
| Ann. Volatility (1Y) | 63.78% | Ann. Volatility (3Y) | 143.95% |
| Sharpe (1Y) | −1.02 | Sharpe (3Y) | 0.12 |
| Max Drawdown (1Y) | −68.60% | Max Drawdown (3Y) | −90.24% |
| Beta (3Y, vs SPY) | −1.00 |
No same-industry peers in the universe for SEQUA.BR.
